Last updated on February 2020

Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer

Brief description of study

This is an open-label, prospective, randomized, controlled, parallel group, multi-center phase III trial to evaluate the Symptom Benefit Rate of trabectedin/PLD in patients with recurrent ovarian cancer who achieve a stabilization of disease after 3 cycles of platinum-based reinduction therapy and with no clinical benefit.

Detailed Study Description

Approximately 330 patients will be randomized in a 1:1 ration to the treatments specified


Arm A - Platinum-based chemotherapy according to investigator's discretion Arm B - Pegylated liposomal doxorubicin 30 mg/m + Trabectedin 1.1 mg/m (q3w)

Clinical Study Identifier: NCT03690739

Find a site near you

Start Over

Evangelisches Krankenhaus Bergisch Gladbach

Bergisch Gladbach, Germany
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.